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Introduction
To improve health and well-being of people with rare dis-
eases and to implement the Council Recommendation of
the European Union on rare diseases the German Federal
Ministry of Health, in cooperation with the Federal
Ministry of Education and Research and the National Alli-
ance of Patient Groups for Rare Diseases, has initiated a
national action league for people with rare diseases -
Nationales Aktionsbündnis für Menschen mit Seltenen
Erkrankungen (NAMSE). NAMSE brings together all key
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bodies and organisations of the German health care system
(27 in total) to enable concerted action based on the adop-
tion of a joint declaration. In four working groups on
“Information, Diagnosis, Care/Centres/Networks and
Research” of NAMSE recommendations are being
developed.
Results
The process of identifying and later labelling national
centres of expertise and their participation in European
Reference Networks is of central importance. Three types
of centres have already been defined on the basis of speci-
fic criteria (Figure 1). These can be differentiated in dis-
ease/disease-group specific medical care functions or
structures and non-disease specific activities (important
for all rare diseases). To guide patients and health care
professionals through the health care system a common,
quality assured information platform, pooling the existing
information services, is discussed.
NAMSE pursues a patient-centred approach respect-
ing the patients and their concerns. Therefore seamless
care pathways are a recurrent theme throughout the
planned measures. They are considered to accelerate the
diagnosis and are of central importance for patient with-
out diagnosis.
Conclusions
Each working group of NAMSE has developed a set of
advices. For all special indicators with targets and a time-
line are being developed to evaluate their effectiveness
after their implementation. Therefore an evaluation board
comments all indicators proposed for the different advices.
All advices have to be prioritised based on their probability
of implementation by a consensus conference. The draft of
German National Action Plan will be assigned to the
Federal Ministry of Health in 2013.
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